Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT01369199 Terminated - Hepatitis B Clinical Trials

Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

HBRN
Start date: May 2012
Phase: Phase 3
Study type: Interventional

The investigators evaluated the safety and efficacy of a short lead-in course (8 weeks) of entecavir followed by combination of entecavir plus peginterferon alfa-2a for 40 weeks.

NCT ID: NCT01368497 Completed - Hepatitis B Clinical Trials

Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

Start date: September 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-<18 years old with immunotolerant chronic hepatitis B.

NCT ID: NCT01366638 Completed - Clinical trials for Hepatitis C, Chronic

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or treatment-experienced (prior relapser or non-responder to Interferon-based therapy) in Japan.

NCT ID: NCT01362517 Completed - Hepatitis B Clinical Trials

Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B

Start date: April 2010
Phase: Phase 3
Study type: Interventional

The aim of this study was to evaluate the immunogenicity and safety of the Quinvaxem vaccine (a liquid combination vaccine against diphtheria, tetanus, B. pertussis, hepatitis B and H. influenzae Type B). Healthy Vietnamese infants received three doses of vaccine at 2, 3 and 4 months of age according to the local Expanded Programme on Immunisation (EPI) schedule

NCT ID: NCT01360970 Completed - Clinical trials for Response to Hepatitis A Vaccine

Hepatitis A Vaccine in Patients With Immunomodulating Drugs

Start date: September 2009
Phase: Phase 2
Study type: Interventional

Hepatitis A vaccine is the most frequently used traveller's vaccine, yet data on its ability to induce protective immunity in immunosuppressed travellers are scarce. The investigators assess the hepatitis A virus (HAV) antibody response in patients with rheumatoid arthritis (RA) treated with Tumor Necrosis Factor (TNF) - inhibitors and/or methotrexate (Mtx).

NCT ID: NCT01360892 Recruiting - Chronic Hepatitis B Clinical Trials

Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography

PICTURE
Start date: September 2010
Phase: N/A
Study type: Observational

This is a multi-center cohort study in which the Real-time Tissue Elastography® measurements will predict prospectively the incidence of hepatocellular carcinoma, the incidence and severity of gastroesophageal varices ascites and decompensated cirrhosis in hepatitis B or C patients.

NCT ID: NCT01360879 Recruiting - Chronic Hepatitis B Clinical Trials

Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease

FIBROELAST
Start date: September 2010
Phase: N/A
Study type: Observational

This is a multi-center cross-sectional study in which the Real-time Tissue Elastography® measurements will be collected prospectively from patients with chronic hepatitis B or C virus presenting for liver biopsy.

NCT ID: NCT01359644 Completed - Chronic Hepatitis C Clinical Trials

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24 weeks as measured by sustained virologic response with undetectable HCV RNA 12 weeks post treatment

NCT ID: NCT01358864 Completed - Clinical trials for Hepatitis C, Chronic

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Start date: June 2011
Phase: Phase 3
Study type: Interventional

The aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 48 weeks as compared to PegIFN/RBV alone in chronic GT-1 hepatitis C virus infected patients who failed a prior PegIFN/RBV treatment.

NCT ID: NCT01356901 Completed - Clinical trials for Hepatitis B, Chronic

Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients

Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this observational study is to measure the real-life persistence, adherence and clinical effectiveness of entecavir in patients with chronic Hepatitis B viral infection.